三位克罗恩病患者静脉用乌司奴单抗即刻输注反应：病例报告及文献复习。
Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature.
机构信息
Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Section of Paediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
出版信息
J Crohns Colitis. 2021 Jan 13;15(1):162-164. doi: 10.1093/ecco-jcc/jjaa115.
Abstract
Recently, ustekinumab has been approved for the treatment of Crohn's disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present details of three patients with therapy-refractory Crohn's disease who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.
摘要
最近，乌司奴单抗已被批准用于治疗克罗恩病和溃疡性结肠炎。治疗开始时采用静脉输注诱导剂量，随后采用皮下剂量。我们介绍了 3 例对静脉注射乌司奴单抗治疗有反应的难治性克罗恩病患者的详细情况。其中 2 例患者随后对皮下注射也有反应。讨论了其临床特征和病理生理学。
相似文献
1
Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn's Disease Patients: A Case Report and Review of the Literature.三位克罗恩病患者静脉用乌司奴单抗即刻输注反应：病例报告及文献复习。
J Crohns Colitis. 2021 Jan 13;15(1):162-164. doi: 10.1093/ecco-jcc/jjaa115.
2
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.优特克单抗诱导克罗恩病患者缓解的安全性和有效性：一项以色列多中心研究。
United European Gastroenterol J. 2020 May;8(4):418-424. doi: 10.1177/2050640620902956. Epub 2020 Jan 24.
3
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.乌司奴单抗诱导克罗恩病患者内镜下愈合的疗效。
Gastroenterology. 2018 Oct;155(4):1045-1058. doi: 10.1053/j.gastro.2018.06.035. Epub 2018 Aug 29.
4
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.英夫利昔单抗治疗难治性或不耐受性溃疡性结肠炎的临床疗效。
United European Gastroenterol J. 2020 Feb;8(1):91-98. doi: 10.1177/2050640619895361. Epub 2019 Dec 12.
5
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.乌司奴单抗对克罗恩病患者组织学疾病活动的影响。
Gastroenterology. 2019 Oct;157(4):1019-1031.e7. doi: 10.1053/j.gastro.2019.06.037. Epub 2019 Jul 4.
6
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.用于诱导克罗恩病缓解的抗IL-12/23 p40抗体。
Cochrane Database Syst Rev. 2015 May 5(5):CD007572. doi: 10.1002/14651858.CD007572.pub2.
7
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.乌司奴单抗诱导和维持治疗克罗恩病。
N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.
8
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.乌司奴单抗诱导和维持溃疡性结肠炎的治疗。
N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.
9
Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.优特克单抗在肿瘤坏死因子-α难治性克罗恩病患者诱导治疗中的疗效与安全性：一项系统评价和荟萃分析。
J Comp Eff Res. 2017 Oct;6(7):601-612. doi: 10.2217/cer-2017-0022. Epub 2017 Jun 29.
10
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.英夫利昔单抗剂量升级对标准剂量皮下维持治疗应答不足的克罗恩病患者的疗效。
Aliment Pharmacol Ther. 2020 Jul;52(1):135-142. doi: 10.1111/apt.15784. Epub 2020 May 15.
引用本文的文献
1
Immediate Infusion Reaction to Intravenous Risankizumab-rzaa but Subsequent Tolerance to Subcutaneous Risankizumab-rzaa.静脉注射司库奇尤单抗-rzaa后立即出现输注反应，但随后对皮下注射司库奇尤单抗-rzaa产生耐受。
ACG Case Rep J. 2024 Nov 6;11(11):e01546. doi: 10.14309/crj.0000000000001546. eCollection 2024 Nov.
2
Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease.病例报告：儿童克罗恩病患者静脉注射英夫利昔单抗和皮下注射优特克单抗的输液相关反应
Front Pediatr. 2021 Dec 24;9:670703. doi: 10.3389/fped.2021.670703. eCollection 2021.
本文引用的文献
1
Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease.一名克罗恩病患者对静脉注射优特克单抗过敏，但对皮下注射优特克单抗耐受。
ACG Case Rep J. 2020 Aug 25;7(8):e00449. doi: 10.14309/crj.0000000000000449. eCollection 2020 Aug.
2
SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis.SB5对阿达木单抗具有交叉免疫原性，但对英夫利昔单抗没有：炎症性肠病或类风湿性关节炎患者的结果。
Therap Adv Gastroenterol. 2019 Dec 4;12:1756284819891081. doi: 10.1177/1756284819891081. eCollection 2019.
3
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.乌司奴单抗诱导和维持溃疡性结肠炎的治疗。
N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.
4
Immunogenicity of biologics in inflammatory bowel disease.生物制剂在炎症性肠病中的免疫原性。
Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X17750355. eCollection 2018.
5
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.乌司奴单抗诱导和维持治疗克罗恩病。
N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.
6
Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?英夫利昔单抗和阿达木单抗的免疫原性：其在超敏反应以及治疗效果和安全性调节中起什么作用？
Expert Opin Drug Saf. 2016 Jan;15(1):43-52. doi: 10.1517/14740338.2016.1112375. Epub 2015 Nov 11.
7
B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.用未处理的患者血清通过寡肽微阵列鉴定英夫利昔单抗上的B细胞表位。
J Transl Med. 2015 Oct 29;13:339. doi: 10.1186/s12967-015-0706-7.
8
Infliximab-Related Infusion Reactions: Systematic Review.英夫利昔单抗相关的输注反应：系统评价
J Crohns Colitis. 2015 Sep;9(9):806-15. doi: 10.1093/ecco-jcc/jjv096. Epub 2015 Jun 19.
9
Systemic allergy to EDTA in local anesthetic and radiocontrast media.局部麻醉药和放射造影剂中乙二胺四乙酸（EDTA）的全身性过敏反应。
J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):225-9. doi: 10.1016/j.jaip.2013.12.001.
10
IgE and mast cells in allergic disease.变应性疾病中的 IgE 和肥大细胞。
Nat Med. 2012 May 4;18(5):693-704. doi: 10.1038/nm.2755.
Zotero 插件